Patents by Inventor Sean B. Carroll

Sean B. Carroll has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20040062771
    Abstract: Treating humans and animals intoxicated with a bacterial toxin by administration of antitoxin. Avian antitoxin in an aqueous solution in therapeutic amount that is orally administrable.
    Type: Application
    Filed: September 15, 2003
    Publication date: April 1, 2004
    Applicant: PROMEGA Corporation
    Inventors: Sean B. Carroll, Margaret B. van Boldrik, Christopher M. Clemens
  • Patent number: 6660267
    Abstract: Compositions and methods are described for preventing and treating sepsis in humans and animals. Surgical patients, low birth weight infants, and burn and trauma victims can be treated prophylactically. Methods for treating acute infections are provided with advantages over current therapeutic approaches.
    Type: Grant
    Filed: September 12, 1994
    Date of Patent: December 9, 2003
    Assignee: Promega Corporation
    Inventor: Sean B. Carroll
  • Patent number: 6656468
    Abstract: Treating humans and animals intoxicated with a bacterial toxin by administration of antitoxin. Avian antitoxin in an aqueous solution in therapeutic amount that is orally administrable.
    Type: Grant
    Filed: March 5, 1997
    Date of Patent: December 2, 2003
    Assignee: Promega Corporation
    Inventors: Sean B. Carroll, Margaret B. van Boldrik, Christopher M. Clemens
  • Patent number: 6613326
    Abstract: Effective antitoxins are demonstrated for prophylactic or causal immunotherapy. A method of generating antitoxin composed of highly-pure antibodies is described as an important defense against naturally-occurring plant and/or bacterial toxins.
    Type: Grant
    Filed: September 13, 1994
    Date of Patent: September 2, 2003
    Assignee: Promega Corporation
    Inventors: Sean B. Carroll, Douglas C. Stafford, Margaret B. Van Boldrik
  • Patent number: 5904922
    Abstract: Antivenoms to snake, spider, scorpion and jelly fish venoms are produced for treatment of humans and animals, and for analytical use. Polyvalent antivenoms are produced containing immunoglobulin which is greater than fifty percent venom reactive. Purified polyvalent antivenom is derived from a first polyvalent antivenom having two or more monovalent subpopulations, and purified such that greater than fifty percent of the monovalent subpopulations are recovered by weight. The antivenoms can be horse or avian such as chicken antivenom. Chicken antivenom is obtained using a whole venom that is not glutaraldehyde pretreated, and the antivenom contains yolk immunoglobulin. Antivenoms are purified with an antigen matrix containing a single whole venom or a plurality of whole venoms covalently attached to an insoluble support such as aldehyde-activated agarose. Preferably, the whole venoms forming the plurality of whole venoms are selected from the four whole venoms of C. atrox, B. atrox, C. adamanteus and C.
    Type: Grant
    Filed: May 16, 1995
    Date of Patent: May 18, 1999
    Assignee: Ophidian Pharmaceuticals, Inc.
    Inventor: Sean B. Carroll
  • Patent number: 5814477
    Abstract: The present invention includes methods for the production and purification of recombinant clostridial toxin proteins.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: September 29, 1998
    Assignee: Ophidian Pharmaceuticals, Inc.
    Inventors: James A. Williams, John A. Kink, Christopher M. Clemens, Sean B. Carroll
  • Patent number: 5762934
    Abstract: The present invention includes methods and compositions for treating humans and other animals intoxicated with at least one clostridial toxin by administration of antitoxin. In particular, the antitoxin directed against these toxins is produced in avian species. This avian antitoxin is designed so as to be orally administerable in therapeutic amounts and may be in any form (i.e., as a solid or in aqueous solution).
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: June 9, 1998
    Assignee: Ophidian Pharmaceuticals, Inc.
    Inventors: James A. Williams, John A. Kink, Christopher M. Clemens, Sean B. Carroll
  • Patent number: 5719267
    Abstract: Treating humans and animals intoxicated with a bacterial toxin by administration of antitoxin. Avian antitoxin in an aqueous solution in therapeutic amount that is orally administrable.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: February 17, 1998
    Assignee: Ophidian Pharmaceuticals Inc.
    Inventors: Sean B. Carroll, Margaret B. van Boldrik, Christopher M. Clemens
  • Patent number: 5605691
    Abstract: This invention relates to the conversion of denatured proteins to soluble forms which are suitable for injection of humans and other animals. The invention is also suitable for analytical use. This method is applicable to the efficient solubilization of proteins which have varying degrees of solubility.
    Type: Grant
    Filed: September 29, 1993
    Date of Patent: February 25, 1997
    Assignee: Ophidian Pharmaceuticals, Inc.
    Inventor: Sean B. Carroll
  • Patent number: 5601823
    Abstract: The present invention includes methods and compositions for treating humans and other animals intoxicated with at least one Clostridial toxin by administration of antitoxin. In particular, the antitoxin directed against these toxins is produced in avian species. This avian antitoxin is designed so as to be orally administerable in therapeutic amounts and may be in any form (i.e., as a solid or in aqueous solution).
    Type: Grant
    Filed: December 2, 1993
    Date of Patent: February 11, 1997
    Assignee: Ophidian Pharmaceuticals, Inc.
    Inventors: James A. Williams, John A. Kink, Christopher M. Clemens, Sean B. Carroll
  • Patent number: 5599539
    Abstract: Treating humans and animals intoxicated with a bacterial toxin by administration of antitoxin. Avian antitoxin in an aqueous solution in therapeutic amount that is orally administrable.
    Type: Grant
    Filed: June 7, 1994
    Date of Patent: February 4, 1997
    Assignee: Ophidian Pharmaceuticals, Inc.
    Inventors: Sean B. Carroll, Margaret B. van Boldrik, Christopher M. Clemens
  • Patent number: 5545721
    Abstract: Compositions and methods are described for preventing and treating sepsis in humans and other animals. Surgical patients, low birth weight infants, burn and trauma victims, as well as other individuals at risk can be treated prophylactically. Methods for treating acute infections with advantages over current therapeutic approaches are provided. Conjugates and methods of making conjugates for the prevention and treatment of sepsis are described.
    Type: Grant
    Filed: December 17, 1993
    Date of Patent: August 13, 1996
    Assignee: Ophidian Pharmaceuticals, Inc.
    Inventors: Sean B. Carroll, Joseph R. Firca, Charles Pugh, Nisha V. Padhye
  • Patent number: 5443976
    Abstract: Antivenoms to snake, spider, scorpion and jelly fish venoms are produced for the treatment of humans and animals, and for analytical use. The antivenom is purified with an antigen matrix containing a single whole venom or a plurality of whole venoms covalently attached to an insoluble support such as aldehyde-activated agarose. Preferably, the whole venoms forming the plurality of whole venoms are selected from the four whole venoms from C. atrox, B. atrox, C. adamanteus and C. durissus terrificus. A combination of immobilized C. atrox and C. durissus terrificus whole venoms can substantially purify antivenom reactive with all four venoms. The antivenom can be horse or avian such as chicken antivenom.
    Type: Grant
    Filed: July 14, 1994
    Date of Patent: August 22, 1995
    Inventor: Sean B. Carroll
  • Patent number: 5340923
    Abstract: Antivenoms suitable for treatment of humans and animals as well as for analytical use. A method wherein individual venoms are used to immunize and the resulting antivenoms are, thereafter, purified individually prior to mixing. Immunization is performed in a mammalian or avian host species.
    Type: Grant
    Filed: November 17, 1992
    Date of Patent: August 23, 1994
    Assignee: Ophidian Pharmaceuticals, Inc.
    Inventor: Sean B. Carroll
  • Patent number: 5196193
    Abstract: The production of antivenoms in non-mammals and improvements in the effectiveness of both non-mammalian antivenoms and mammalian antivenoms so that they are more suitable for treatment of humans and animals as well as for analytical use.
    Type: Grant
    Filed: October 31, 1989
    Date of Patent: March 23, 1993
    Assignee: Ophidian Pharmaceuticals, Inc.
    Inventor: Sean B. Carroll